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a  b  s  t  r  a  c  t
Background: The outstanding innovations made by early diagnosis, novel surgical techniques,
effective chemotherapy regimens and conformal radiotherapy, have significantly improved
patients overall survival and quality of life. Multidisciplinary approach to cancer has also
led  to an increased prevalence of patients with few, organ-confined metastases, who can
experience long-term survival even if their disease is no longer localized. Liver is one of
the  most common site for metastatic disease from several cancers, and when metastatic
disease is confined to liver, given the ability of this organ to regenerate almost to its optimal
volume, surgical resection represents the standard of care because is associated with a better
prognosis. Approximately 70–90% of liver metastases, however, are unresectable and a safe,
effective alternative therapeutic option is necessary for these patients.
Materials and methods: A review of the current literature was performed to analyze the role of
SBRT in treating liver metastases from different cancers. A literature search using the terms
“SBRT” and “liver metastases” was carried out in PUBMED.
Results: Stereotactic body radiation therapy has shown to provide promising results in the
treatment of liver metastases, thanks to the ability of this procedure to deliver a conformalhigh dose of radiation to the target lesion and a minimal dose to surrounding critical tissues.
Conclusion: Stereotactic body radiation therapy is a non-invasive, well-tolerated and effective
treatment for patients with liver metastases not suitable for surgical resection.
©  2014 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o. All rights reserved.1.  Background
Over the last decades, innovations made by modern oncol-
ogy, in terms of early diagnosis, novel surgical techniques,
effective chemotherapy regimens and conformal radiothe-
rapy, have significantly improved patients overall survival
and quality of life.1 The multidisciplinary approach to
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few, organ-confined metastases, who can experience long-
term survival even if their disease is no longer localized. The
concept of oligometastatic state was first proposed in 199556, 20089 Rozzano, Milano, Italy. Tel.: +39 0282247244;
by Hellman and Weichselbaum, who suggested the existence
of an intermediate tumour state for most cancers, stand-
ing between purely localized lesions and a widely metastatic
disease.2
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An attractive consequence of the presence of this clinically
ignificant oligometastatic state is that this subpopulation of
atients should be amenable to curative therapeutic strate-
ies. The successful surgical resection or radiation ablation
f one or a small number of pulmonary, hepatic, or even
rain metastases is the evidence of a limited form of the
ligometastatic state.3
Liver is the most common site of metastastic disease from
ost cancers and when metastatic disease is confined to this
rgan, surgical resection has proved to obtain an improved
urvival, as compared to other therapeutic strategies.4,5 Colo-
ectal cancer (CRC) is one of the tumours that most often
resents with solitary or oligometastasic disease, commonly
n the liver. It is estimated, indeed, that 30–70% of patients
ith CRC will develop liver metastases and in this subset of
atients, the overall survival is about 31% and 1% at 1 year and
t 4 years, respectively, with a median survival ranging from
 to 12 months.6 Historically, surgical resection of CRC liver
etastases improves overall survival, with 1 and 5-year rates
f 90–95% and 30–60%, respectively, with a median overall sur-
ival of 40–53 months.7–13
For partially resectable or unresectable patients, the intro-
uction of modern chemotherapy regimens in the induction
reatment of colorectal liver metastases allowed downsiz-
ng the disease, favouring surgical resection and, potentially,
urvival.14 On the other hand, chemotherapy can also
orsen hepatic function and increase the rate of perioper-
tive complications. Recent studies have demonstrated that
hemotherapy may produce multiple toxic effects on the
nderlying liver parenchyma, ranging from steatosis to steato-
epatitis and sinusoidal obstruction syndrome.15
Only 10–50% of patients are suitable for surgical resection
ecause of technical difficulties, unfavourable tumour factors
r patient comorbidities.12,13 In these patients, a safe and
ffective alternative therapeutic option is necessary.
In the last decade, minimally invasive loco-regional
pproaches were introduced as an alternative to surgery,
ncluding radiofrequency ablation (RFA), which causes tissue
ocal coagulative necrosis.
Nevertheless, this technique has some limits, mostly
elated to lesion size and location (lesions higher than 3 cm
f diameter or in proximity of major blood vessels, the
ain biliary tract or the gallbladder, or just beneath the
iaphragm).20–23
This review aims to better define the role of stereotac-
ic body radiotherapy in the treatment of colorectal cancer
iver metastases through a revision of the current literature,
n order to provide practice guidelines on the use of this novel
trategy.
.  The  role  of  stereotactic  body  radiation
herapy  (SBRT)  for  the  treatment  of  liver
etastases
istorically, radiation therapy has had a limited role in the
reatment of liver metastases. The low tolerance of liver tis-
ue to irradiation raises the risk of the radiation-induced liver
isease (RILD). RILD syndrome is characterized by anicteric
scites with elevation of alkaline phosphatase and livertherapy 2 0 ( 2 0 1 5 ) 464–471 465
transaminases, which occurs two weeks to 4 months after
radiotherapy and can results in liver failure and death.24
From the classic work of Ingold16 and the historical report
by Emami  et al.,17 several radiobiological studies demon-
strated that the liver has a parallel architecture, and that
a life-threatening liver toxicity, as documented in previous
experiences involving the irradiation of the whole liver, is
quite infrequent when only a part of liver is irradiated. Modern
3D-radiotherapy, indeed, allows delivering of a very confor-
mal  radiation dose to the tumour and a minimal radiation
dose to surrounding critical tissues, thus validating the impor-
tance of the mean radiation dose delivered to normal tissue.24
Moreover, recent studies have demonstrated that an increased
toxicity risk is associated to the mean dose delivered to
liver.24,37
Unlike standard radiotherapy, which delivers conventional
fractions (ranging from 1.5 to 3 Gy) to a larger volume, SBRT
entails precise delivery of high-dose in a single or a few frac-
tions (1–6 fractions).25,26
Analysis of the literature demonstrates that SBRT was
used in several primary and secondary tumours.27,28 No
randomized Phase III data have been published. Liver metas-
tases were the target of SBRT in five retrospective29–33 and 8
prospective34–41 studies. The latter are described in detail in
Table 1.
As expected, colorectal, breast and lung cancer were the
primary tumours most frequently represented and treated.
Patients had a good performance status (Eastern Cooperative
Oncology Group 0–1 or Karnofsky >70), absent or stable extra-
hepatic disease, adequate hepatic volume and function and
less than 5 lesions with tumour size <6 cm.
Two trials and one pooled analysis investigated the role of
SBRT on hepatic lesion from a single primary tumour type,
including 44, 20 and 86 patients respectively, treated for colo-
rectal cancer liver metastases.39,40,44
Two studies employed a single fraction of SBRT with a pre-
scription dose ranging from 14 to 30 Gy. In these trials, 1-year
local control ranged from 71% to 77%, 1-year OS from 72%
to 80% and toxicity from G0 to G2 (2 cases of G2 gastroin-
testinal late toxicity and 2 cases of G2 late toxicity of soft
tissue/rib).34,36
In 5 trials and 1 pooled analysis, doses prescription ranged
from 25 to 60 Gy in 3–6 fractions, with a local control rate
ranging from 70% to 100% and 60% to 90% at 1 and 2 years,
respectively.
One and 2 years OS rates were 70–80% and 30–73% respec-
tively, with a median overall survival rate ranging from 10 to
34 months.35,37–40,44
Correlation between prognostic factors and both local con-
trol and overall survival were analyzed by Rusthoven et al.
A significant connection between dose prescription, tumour
size and local failure rate was demonstrated. This phase I/II
study enrolled 47 patients with a prescription dose of 60 Gy in 3
fractions and showed that 1-year LC decreased significantly in
the subgroup of lesions with diameter >3 cm.37 In 2011, Chang
et al. confirmed the correlation between dose prescription and
local control and suggested a dose ≥48 Gy for a 3 fractions
SBRT regimen. In this pooled analysis, the absence of active





































Table 1 – Outcomes of published Phase I–II trial.
Authors No. of patients No. of lesions Histology Total dose/frs Toxicity Local control Overall survival
Scorsetti, 2013
Phase II




75 Gy/3 frs No RILD, 1 case
G3 late toxicity
(chest wall pain)
1-yr  LC, 94% 1–yr OS 83.5%
Goodman, 2010
Phase I








4  cases of G2 late








27  Not reported CRC (11)
Other (16)




















































2 cases G3 liver
toxicities
2-yr LC, 86% 2-yr OS, 62%
Hoyer, 2006
Phase II
64  (44 Mets) 141 (lung + liver + other
sites)
CRC (44) 45 Gy/3 frs 1 liver failure
2 severe late GI
toxicities
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In 2013, the preliminary results of a phase II trial with a
igher prescription dose was published.41 With a 1-year LC
ate of 94%, Scorsetti et al. showed no statistical differences
n local control rates for lesions with diameter ≤3 cm com-
ared with those >3 cm,  when a prescription dose of 75 Gy in
 fractions was delivered.41
Most studies with a 3–6 fractions regimen showed a low
oxicity profile with a ≥G3 toxicity rate of 1–10% and an inci-
ence of RILD less than 1%. Lee et al.35 had no RILD in 68
atients treated with 6 fractions and median liver dose of
6.9 Gy (range, 3–22 Gy). In two Phase I/II studies,37,41 reporting
n 47 and 61 patients, respectively, no RILD was observed using
 dose constraint allowing no more  than 700 mL  of uninvolved
iver to receive 15 Gy or greater in 3 fractions. The most com-
on  G2 toxicities included a transient hepatic transaminase
ncrease within 3 months of SBRT39,41 and gastrointestinal,
oft-tissue and bone complications, related to lesions close
o the duodenum, bowel, skin and ribs. Duodenal ulceration
nd intestinal perforation were observed in 3 patients with
aximum doses greater than 30 Gy in 3 fractions to the duo-
enum and bowel.40 One case of Grade 3 soft-tissue toxicity
as observed for a 48 Gy dose in 3 fractions to subcutaneous
issue.37 In 2 patients, nontraumatic rib fractures were experi-
nced for maximum doses of 51.8 Gy and 66.2 Gy in 6 fractions
o 0.5 cm3.35 One patient suffered from chronic chest wall pain
3, which resolved within 1 year after SBRT with a prescription
ose of 75 Gy in 3 fractions.41
.  Stereotactic  body  radiation  therapy
SBRT)  for  liver  metastases:  patients  selection
ultidisciplinary assessment is recommended to identify
atients with liver metastases candidate to SBRT. According
o the current literature and on the basis of lesion’s number
nd diameter, distance from OARs, liver function and free liver
olume, SBRT may be considered as follows:
 Indicated: patients with a good performance status (Eastern
Cooperative Oncology Group 0–1 or Karnofsky >70), number
of hepatic lesions ≤3, size lesions ≤3 cm,  lesion distance
from OARs >8 mm,  good liver function and free liver volume
>1000 cm3.
 Borderline: patients with 4 liver metastases, diameter >3
and ≤6 cm,  OARs distance >5 and ≤8 mm,  moderate liver
function and free liver ≥700 and <1000 cm3.
 Contra-indicated: patients with ≥ 5hepatic lesions, diame-
ter >6 cm,  OARs distance ≤5 mm,  inadequate liver function
and free liver volume <700 cm3.
Age is not considered in selection criteria, as even elderly
nd fragile patients can safely undergo SBRT. This non-
nvasive and well-tolerated therapy is a good option for
atients unsuitable for surgery.The intrinsic radio-sensitivity of tumours is not an issue,
s SBRT can be used regardless of histopathology thanks to
he use of ablative doses, with similar local control rates in
adioresistant and radiosensitive primary tumour.therapy 2 0 ( 2 0 1 5 ) 464–471 467
4.  Stereotactic  body  radiation  therapy
(SBRT)  for  liver  metastases:  target  definition,
planning  and  delivery
SBRT requires precise target definition, planning and
delivery.48 Practice guidelines for SBRT were published in 2010
by ASTRO and ACR.25,26 To ensure the delivery accuracy, the
target position is checked before or during SBRT treatment, by
an integrated image  acquisition system (image-guided radia-
tion therapy or IGRT).25,26
According to ICRU 82,42 the clinical target volume (CTV)
is defined as equal to the gross tumour volume (GTV). Dur-
ing simulation phase, all the immobilization devices offered
by modern technologies in order to reduce organ motion and
maximize reproducibility and accuracy during each fraction,
are required. An abdominal compression and a 4D-CT scan can
be useful, since a significant liver motion according to respi-
ratory cycle has been widely demonstrated.41 A three-phase
contrast-enhanced CT scan should be employed, because not
all hepatic lesions can be easily identified with a contrast-
free CT-scan. For this reason, positron emission tomography
(PET) and/or magnetic resonance (MRI) could be necessary to
improve target definition. If 4D-CT scan is performed, an inter-
nal target volume (ITV) is the volume encompassing all GTVs
in the different phase of respiratory cycle. ITV is defined as
internal margin (IM).
A margin to compensate set-up errors is added to ITV (plan-
ning target volume, PTV). If 4D-CT scan is not acquired and ITV
is not defined, the PTV is generated from CTV. A geometrical
margin is added to CTV to rectify the uncertainties of set-up
and internal margin.42 Fig. 1 shows these volumes.
In order to obtain a high conformal dose distribution with
the maximum sparing of organs at risk, intensity modulated
RT (IMRT) or volumetric arc radiation therapy (VMAT) should
be employed,25,26 as showed in Fig. 2.
Image  guided radiation therapy (IGRT) should be performed
before each daily session to check patient and tumour posi-
tion; in selected patients, fiducials markers implantation
could be useful for target localization.43 In patients who  had
previous surgery, surgical clips could be used as markers.41
5.  Stereotactic  body  radiation  therapy
(SBRT)  for  liver  metastases:  dose  prescription
and  response  evaluation
There are several schedules of treatment for SBRT in liver
metastases in current literature. In Chang et al. experience,
local control is correlated with total dose.44 Prescription dose
≥48 Gy in 3 fractions should be considered, if allowed by nor-
mal  tissue constraints. If lesion is smaller than 3 cm,  a total
dose of 60 Gy could be suggested.37 For lesions greater than
3 cm,  a dose escalation should be cautiously evaluated up
75 Gy in 3 fractions.41
Table 2 shows recommended dose prescription according
to lesion size. Table 3 summarizes recommended dose con-
straints for organs at risk (OARs).37,41
The criteria established by the European Organization
for Research and Treatment of Cancer Response Evaluation
468  reports of practical oncology and radiotherapy 2 0 ( 2 0 1 5 ) 464–471
Fig. 1 – Examples of target volumes delineation for liver SBRT.
tases SBRT with VMAT  technique.
Table 3 – Recommended OARs dose constraints for SBRTFig. 2 – Example of liver metas
Criteria in Solid Tumours (EORTC-RECIST) must be used to
evaluate tumour response.18 PET Response Criteria in Solid
Tumours (PERCIST) are recommended, if PET-CT is performed
before SBRT.19 Fig. 3 shows the metabolic complete response
of hepatic lesion 6 months after SBRT.
Table 2 – Dose prescription for SBRT in 3 fractions
recommended according to lesion size.
Lesion size Prescription dose
≤3 cm 48–60 Gy
>3–6 cm 60–75 Gy
of liver metastasis in 3 fractions.
OAR Dose-volume limits
Healthy liver (total liver volume minus
cumulative GTV)
>700 cm3 at <15 Gya
Stomach, duodenum, small intestine D 3 cm3 at <21 Gyb
Both kidneys V 15 Gy at <35%
Spinal cord D 1 cm3 at <18 Gy
Heart D 1 cm3 at <30 Gy
Rib D 30 cm3 at <30 Gy
a Volume of healthy liver >1000 cm3.
b Distance by GTV >8 mm.
reports of practical oncology and radiotherapy 2 0 ( 2 0 1 5 ) 464–471 469




















hether or not SBRT plays a significant role in the manage-
ent of liver metastases can only be evaluated by means of
andomized clinical trials that compare the standard of care
lone or with the addition of SBRT, such as the ongoing ran-
omized trial NCT01233544 (RFA versus SBRT).46 Combination
ith chemotherapy and targeted therapy could be investi-
ated to reduce the incidence of extra-field recurrences.47
Further studies with a homogeneous selection of patients
n the basis of histopathology, previous treatments and prog-
osis are advisable to better understand the real impact of
BRT on survival. Literature review shows that stereotactic
ody radiation therapy is a non-invasive, well-tolerated and
ffective treatment for liver metastases. It represents a valid,
romising alternative for patients not suitable for surgical
esection.onflict  of  interest
one declared.Financial  disclosure
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